ATF5在抵抗癌细胞死亡中的机制及其 作为治疗靶点的价值
Mechanisms of ATF5 in Cancer Cell Death Resistance and Therapeutic Target Potential
DOI: 10.12677/acm.2026.162564, PDF,   
作者: 王伟梅, 张贵海*：暨南大学珠海临床医学院(珠海市人民医院，北京理工大学附属医院)肿瘤内科，广东 珠海
关键词: 细胞死亡；耐药性；ATF5；细胞凋亡；自噬；失巢凋亡；Cell Death； Drug Resistance； ATF5； Apoptosis； Autophagy； Anoikis
摘要: 细胞死亡对机体内部环境稳定起着重要的保障作用，其调控紊乱与多种疾病相关，尤其是与恶性肿瘤的发生发展进程存在着紧密关联。逃避细胞死亡被看作是癌症的主要特征之一。虽然现有的肿瘤治疗策略像放射治疗和化学药物治疗能有效杀伤肿瘤细胞，但癌细胞借助多种复杂的分子机制会产生对治疗药物的耐受性，所以药物耐受性成为当前肿瘤学领域研究的重点与难点。研究显示，激活转录因子5 (ATF5)的表达与各类恶性肿瘤患者的预后生存率呈显著负相关。ATF5在癌细胞的存活和增殖中发挥着重要作用，可以选择性地抵抗癌细胞的死亡，从而诱导治疗抗性。本文系统综述ATF5介导癌细胞抵抗不同死亡模式如细胞凋亡、自噬及失巢凋亡的分子机制，目的是阐明其作为潜在治疗靶点的科学价值与应用前景。
Abstract: Cell death plays a crucial role in maintaining the internal homeostasis of the organism, and its dysregulation is associated with various diseases, especially with a close connection to the occurrence and progression of malignant tumors. Evasion of cell death is considered one of the main characteristics of cancer. Although current tumor treatment strategies, such as radiotherapy and chemotherapy, can effectively kill tumor cells, cancer cells can develop tolerance to therapeutic drugs through various complex molecular mechanisms, making drug resistance a current focus and difficulty in the field of oncology. Studies have shown that the expression of activating transcription factor 5 (ATF5) is significantly negatively correlated with the prognostic survival rates of patients with various malignant tumors. ATF5 plays an important role in the survival and proliferation of cancer cells, can selectively resist the death of cancer cells, and thereby induce therapeutic resistance. This article systematically reviews the molecular mechanisms by which ATF5 mediates cancer cells’ resistance to different death modes such as apoptosis, autophagy, and anoikis, aiming to clarify its scientific value and application prospects as a potential therapeutic target.
文章引用：王伟梅, 张贵海. ATF5在抵抗癌细胞死亡中的机制及其 作为治疗靶点的价值[J]. 临床医学进展, 2026, 16(2): 1717-1724. https://doi.org/10.12677/acm.2026.162564

参考文献

[1] Newton, K., Strasser, A., Kayagaki, N. and Dixit, V.M. (2024) Cell Death. Cell, 187, 235-256. [Google Scholar] [CrossRef] [PubMed]
[2] Qi, K., Mu, Y., Hu, Y., Li, J. and Liu, J. (2025) Comprehensive Landscape of Cell Death Mechanisms: From Molecular Cross-Talk to Therapeutic Innovation in Oncology. Frontiers in Cell and Developmental Biology, 13, Article 1611055. [Google Scholar] [CrossRef] [PubMed]
[3] Gong, L., Huang, D., Shi, Y., Liang, Z. and Bu, H. (2023) Regulated Cell Death in Cancer: From Pathogenesis to Treatment. Chinese Medical Journal, 136, 653-665. [Google Scholar] [CrossRef] [PubMed]
[4] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
[5] D’Amico, M. and De Amicis, F. (2024) Challenges of Regulated Cell Death: Implications for Therapy Resistance in Cancer. Cells, 13, Article 1083. [Google Scholar] [CrossRef] [PubMed]
[6] Das, C.K., Mandal, M. and Kögel, D. (2018) Pro-Survival Autophagy and Cancer Cell Resistance to Therapy. Cancer and Metastasis Reviews, 37, 749-766. [Google Scholar] [CrossRef] [PubMed]
[7] Du, Y., Liu, X., Wang, L. and Chen, S. (2024) Editorial: New Strategies for Reversing Cancer Therapy Resistance. Frontiers in Pharmacology, 15, Article 1411519. [Google Scholar] [CrossRef] [PubMed]
[8] Sun, X., Angelastro, J.M., Merino, D., Zhou, Q., Siegelin, M.D. and Greene, L.A. (2019) Dominant-Negative ATF5 Rapidly Depletes Survivin in Tumor Cells. Cell Death & Disease, 10, Article No. 709. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, S.Z., Ou, J., Zhu, L.J. and Green, M.R. (2012) Transcription Factor ATF5 Is Required for Terminal Differentiation and Survival of Olfactory Sensory Neurons. Proceedings of the National Academy of Sciences, 109, 18589-18594. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, T., Zhang, Y., Chen, L., Thomas, E.R., Yu, W., Cheng, B., et al. (2023) The Potential Roles of ATF Family in the Treatment of Alzheimer’s Disease. Biomedicine & Pharmacotherapy, 161, Article 114544. [Google Scholar] [CrossRef] [PubMed]
[11] Torres-Peraza, J.F., Engel, T., Martín-Ibáñez, R., Sanz-Rodríguez, A., Fernández-Fernández, M.R., Esgleas, M., et al. (2013) Protective Neuronal Induction of ATF5 in Endoplasmic Reticulum Stress Induced by Status Epilepticus. Brain, 136, 1161-1176. [Google Scholar] [CrossRef] [PubMed]
[12] Izumi, S., Saito, A., Kanemoto, S., Kawasaki, N., Asada, R., Iwamoto, H., et al. (2012) The Endoplasmic Reticulum Stress Transducer BBF2H7 Suppresses Apoptosis by Activating the ATF5-MCL1 Pathway in Growth Plate Cartilage. Journal of Biological Chemistry, 287, 36190-36200. [Google Scholar] [CrossRef] [PubMed]
[13] Juliana, C.A., Yang, J., Rozo, A.V., Good, A., Groff, D.N., Wang, S., et al. (2017) ATF5 Regulates β-Cell Survival during Stress. Proceedings of the National Academy of Sciences, 114, 1341-1346. [Google Scholar] [CrossRef] [PubMed]
[14] Fiorese, C.J., Schulz, A.M., Lin, Y., Rosin, N., Pellegrino, M.W. and Haynes, C.M. (2016) The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR. Current Biology, 26, 2037-2043. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, H., Lin, G. and Zhang, Z. (2007) ATF5 Promotes Cell Survival through Transcriptional Activation of Hsp27 in H9C2 Cells. Cell Biology International, 31, 1309-1315. [Google Scholar] [CrossRef] [PubMed]
[16] Feldheim, J., Kessler, A.F., Schmitt, D., Wilczek, L., Linsenmann, T., Dahlmann, M., et al. (2018) Expression of Activating Transcription Factor 5 (ATF5) Is Increased in Astrocytomas of Different WHO Grades and Correlates with Survival of Glioblastoma Patients. OncoTargets and Therapy, 11, 8673-8684. [Google Scholar] [CrossRef] [PubMed]
[17] Ben-Shmuel, S., Rashed, R., Rostoker, R., Isakov, E., Shen-Orr, Z. and LeRoith, D. (2017) Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. Frontiers in Endocrinology, 8, Article 173. [Google Scholar] [CrossRef] [PubMed]
[18] Mittal, A.K., Hegde, G.V., Aoun, P., et al. (2007) Molecular Basis of Aggressive Disease in Chronic Lymphocytic Leukemia Patients with 11q Deletion and Trisomy 12 Chromosomal Abnormalities. International Journal of Molecular Medicine, 20, 461-469. [Google Scholar] [CrossRef] 
[19] Ishihara, S., Yasuda, M., Ishizu, A., Ishikawa, M., Shirato, H. and Haga, H. (2015) Activating Transcription Factor 5 Enhances Radioresistance and Malignancy in Cancer Cells. Oncotarget, 6, 4602-4614. [Google Scholar] [CrossRef] [PubMed]
[20] Angelastro, J.M. (2017) Targeting ATF5 in Cancer. Trends in Cancer, 3, 471-474. [Google Scholar] [CrossRef] [PubMed]
[21] Acosta, J., Wang, W. and Feldser, D.M. (2018) Off and Back-On Again: A Tumor Suppressor’s Tale. Oncogene, 37, 3058-3069. [Google Scholar] [CrossRef] [PubMed]
[22] Nishioka, T., Miyai, Y., Haga, H., Kawabata, K., Shirato, H., Homma, A., et al. (2009) Novel Function of Transcription Factor ATF5: Blockade of p53-Dependent Apoptosis Induced by Ionizing Irradiation. Cell Structure and Function, 34, 17-22. [Google Scholar] [CrossRef] [PubMed]
[23] Li, G., Li, W., Angelastro, J.M., Greene, L.A. and Liu, D.X. (2009) Identification of a Novel DNA Binding Site and a Transcriptional Target for Activating Transcription Factor 5 in C6 Glioma and MCF-7 Breast Cancer Cells. Molecular Cancer Research, 7, 933-943. [Google Scholar] [CrossRef] [PubMed]
[24] Ishihara, S., Enomoto, A., Sakai, A., Iida, T., Tange, S., Kioka, N., et al. (2025) Stiff Extracellular Matrix Activates the Transcription Factor ATF5 to Promote the Proliferation of Cancer Cells. iScience, 28, Article 112057. [Google Scholar] [CrossRef] [PubMed]
[25] Dolcet, X., Llobet, D., Pallares, J. and Matias-Guiu, X. (2005) NF-kB in Development and Progression of Human Cancer. Virchows Archiv, 446, 475-482. [Google Scholar] [CrossRef] [PubMed]
[26] Ma, J., Ma, S., Wang, T. And Zhang, Y. (2019) Knock-Down of ATF5 Gene Expression by RNA Interference Down-Regulates NF-κB Signaling to Induce Apoptosis in Glioma Cells. Chinese Journal of Pathophysiology, 35, 1470-1474.
[27] Sha, G., Jiang, Z., Zhang, W., Jiang, C., Wang, D. and Tang, D. (2023) The Multifunction of HSP70 in Cancer: Guardian or Traitor to the Survival of Tumor Cells and the Next Potential Therapeutic Target. International Immunopharmacology, 122, Article 110492. [Google Scholar] [CrossRef] [PubMed]
[28] Li, G., Xu, Y., Guan, D., Liu, Z. and Liu, D.X. (2011) HSP70 Protein Promotes Survival of C6 and U87 Glioma Cells by Inhibition of ATF5 Degradation. Journal of Biological Chemistry, 286, 20251-20259. [Google Scholar] [CrossRef] [PubMed]
[29] Dluzen, D., Li, G., Tacelosky, D., Moreau, M. and Liu, D.X. (2011) BCL-2 Is a Downstream Target of ATF5 That Mediates the Prosurvival Function of ATF5 in a Cell Type-Dependent Manner. Journal of Biological Chemistry, 286, 7705-7713. [Google Scholar] [CrossRef] [PubMed]
[30] Chen, A., Qian, D., Wang, B., Hu, M., Lu, J., Qi, Y., et al. (2012) ATF5 Is Overexpressed in Epithelial Ovarian Carcinomas and Interference with Its Function Increases Apoptosis through the Downregulation of BCL-2 in SKOV-3 Cells. International Journal of Gynecological Pathology, 31, 532-537. [Google Scholar] [CrossRef] [PubMed]
[31] Hu, M., Wang, B., Qian, D., et al. (2012) Interference with ATF5 Function Enhances the Sensitivity of Human Pancreatic Cancer Cells to Paclitaxel-Induced Apoptosis. Anticancer Research, 32, 4385-4394.
[32] Kondo, S., Saito, A., Hino, S., Murakami, T., Ogata, M., Kanemoto, S., et al. (2007) BBF2H7, a Novel Transmembrane bZIP Transcription Factor, Is a New Type of Endoplasmic Reticulum Stress Transducer. Molecular and Cellular Biology, 27, 1716-1729. [Google Scholar] [CrossRef] [PubMed]
[33] Sheng, Z., Li, L., Zhu, L.J., Smith, T.W., Demers, A., Ross, A.H., et al. (2010) A Genome-Wide RNA Interference Screen Reveals an Essential CREB3L2-ATF5-MCL1 Survival Pathway in Malignant Glioma with Therapeutic Implications. Nature Medicine, 16, 671-677. [Google Scholar] [CrossRef] [PubMed]
[34] Liu, S., Yao, S., Yang, H., Liu, S. and Wang, Y. (2023) Autophagy: Regulator of Cell Death. Cell Death & Disease, 14, Article No. 648. [Google Scholar] [CrossRef] [PubMed]
[35] Ishaq, M., Ojha, R., Sharma, A.P. and Singh, S.K. (2020) Autophagy in Cancer: Recent Advances and Future Directions. Seminars in Cancer Biology, 66, 171-181. [Google Scholar] [CrossRef] [PubMed]
[36] Das, S., Joshi, M.B., Parashiva, G.K. and Rao, S.B.S. (2020) Stimulation of Cytoprotective Autophagy and Components of Mitochondrial Biogenesis/Proteostasis in Response to Ionizing Radiation as a Credible Pro-Survival Strategy. Free Radical Biology and Medicine, 152, 715-727. [Google Scholar] [CrossRef] [PubMed]
[37] Sheng, Z., Ma, L., Sun, J.E., Zhu, L.J. and Green, M.R. (2011) BCR-ABL Suppresses Autophagy through Atf5-Mediated Regulation of mTOR Transcription. Blood, 118, 2840-2848. [Google Scholar] [CrossRef] [PubMed]
[38] Li, Y., Liu, F., Cai, Q., Deng, L., et al. (2025) Invasion and Metastasis in Cancer: Molecular Insights and Therapeutic Targets. Signal Transduction and Targeted Therapy, 10, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, Y., Cheng, S., Fleishman, J.S., Chen, J., Tang, H., Chen, Z., et al. (2024) Targeting Anoikis Resistance as a Strategy for Cancer Therapy. Drug Resistance Updates, 75, Article 101099. [Google Scholar] [CrossRef] [PubMed]
[40] Banerjee, D., Boboila, S., Okochi, S., Angelastro, J.M., Kadenhe-Chiweshe, A.V., Lopez, G., et al. (2023) Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. Cancer Research Communications, 3, 2518-2530. [Google Scholar] [CrossRef] [PubMed]
[41] Dixon, S.J. and Olzmann, J.A. (2024) The Cell Biology of Ferroptosis. Nature Reviews Molecular Cell Biology, 25, 424-442. [Google Scholar] [CrossRef] [PubMed]
[42] Yang, W.S. and Stockwell, B.R. (2008) Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-Ras-Harboring Cancer Cells. Chemistry & Biology, 15, 234-245. [Google Scholar] [CrossRef] [PubMed]
[43] Richardson, D.R., Lane, D.J.R., Becker, E.M., et al. (2010) Mitochondrial Iron Trafficking and the Integration of Iron Metabolism between the Mitochondrion and Cytosol. Proceedings of the National Academy of Sciences, 107, 10775-10782. [Google Scholar] [CrossRef] [PubMed]
[44] Haynes, C.M. and Ron, D. (2010) The Mitochondrial UPR—Protecting Organelle Protein Homeostasis. Journal of Cell Science, 123, 3849-3855. [Google Scholar] [CrossRef] [PubMed]
[45] Xin, N., Durieux, J., Yang, C., Wolff, S., Kim, H. and Dillin, A. (2022) The UPRmt Preserves Mitochondrial Import to Extend Lifespan. Journal of Cell Biology, 221, e202201071. [Google Scholar] [CrossRef] [PubMed]
[46] Deng, P. and Haynes, C.M. (2017) Mitochondrial Dysfunction in Cancer: Potential Roles of ATF5 and the Mitochondrial UPR. Seminars in Cancer Biology, 47, 43-49. [Google Scholar] [CrossRef] [PubMed]
[47] Moll, J.R., Olive, M. and Vinson, C. (2000) Attractive Interhelical Electrostatic Interactions in the Proline-And Acidic-Rich Region (PAR) Leucine Zipper Subfamily Preclude Heterodimerization with Other Basic Leucine Zipper Subfamilies. Journal of Biological Chemistry, 275, 34826-34832. [Google Scholar] [CrossRef] [PubMed]
[48] Greene, L.A., Lee, H.Y. and Angelastro, J.M. (2008) The Transcription Factor ATF5: Role in Neurodevelopment and Neural Tumors. Journal of Neurochemistry, 108, 11-22. [Google Scholar] [CrossRef] [PubMed]
[49] Cates, C.C., Arias, A.D., Wong, L.S.N., Lamé, M.W., Sidorov, M., Cayanan, G., et al. (2016) Regression/Eradication of Gliomas in Mice by a Systemically-Deliverable ATF5 Dominant-Negative Peptide. Oncotarget, 7, 12718-12730. [Google Scholar] [CrossRef] [PubMed]
[50] Karpel-Massler, G., Horst, B.A., Shu, C., Chau, L., Tsujiuchi, T., Bruce, J.N., et al. (2016) A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Clinical Cancer Research, 22, 4698-4711. [Google Scholar] [CrossRef] [PubMed]

为你推荐